Last reviewed · How we verify
SPD489
SPD489 is a Small molecule drug developed by Shire. It is currently FDA-approved. Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse, Lisdexmfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate.
At a glance
| Generic name | SPD489 |
|---|---|
| Also known as | lisdexamfetamine dimesylate, LDX, Vyvanse, Lisdexmfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, LDX |
| Sponsor | Shire |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder (PHASE3)
- Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (PHASE3)
- Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia (PHASE3)
- SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (PHASE3)
- Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder (PHASE4)
- Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers (PHASE1)
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study (PHASE3)
- Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPD489 CI brief — competitive landscape report
- SPD489 updates RSS · CI watch RSS
- Shire portfolio CI
Frequently asked questions about SPD489
What is SPD489?
SPD489 is a Small molecule drug developed by Shire.
Who makes SPD489?
SPD489 is developed and marketed by Shire (see full Shire pipeline at /company/shire).
Is SPD489 also known as anything else?
SPD489 is also known as lisdexamfetamine dimesylate, LDX, Vyvanse, Lisdexmfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, LDX.
What development phase is SPD489 in?
SPD489 is FDA-approved (marketed).
Related
- Manufacturer: Shire — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse, Lisdexmfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, Vyvanse, Lisdexamfetamine dimesylate, LDX